August 9, 2016
Biosimilar medications designed to give patients more options may instead become health plans’ newest tool for limiting patient access.
July 20, 2016
July 12 and 13 hearings of the FDA’s Arthritis Advisory Committee cleared the way for two new biosimilars, adalimumab and etanercept. The committee unanimously supported manufacturers’ applications for the drugs – but that wasn’t the only point of consensus. Participants and even committee members expressed concerns about unfinished regulatory policy and the need to prioritize patient safety.
June 17, 2016
Co-pays are high and health care is far from optimal for Americans with chronic obstructive pulmonary disease (COPD), says a new report from The Lancet Respiratory Medicine Commission.
April 11, 2016
A physician tells a story in the Alliance for Patient Access’ oncology working group white paper about attending the funeral of one of his cancer patients.
April 8, 2016
Patients with respiratory conditions are often not sick enough to be in critical care but not well enough to deal with their symptoms without consistent intervention. So explains a newly released white paper from the Institute for Patient Access and the Alliance for Patient Access’ Respiratory Therapy Access Working Group.
February 9, 2016
Patients with chronic or serious medical conditions must sometimes work with physicians for months to identify a medication that’s effective for them. But as a new video from the Alliance for Patient Access explains, patients may discover that this trial-and-error process was in vain.
May 28, 2015
Insurers have a new strategy for reducing the costs of injectable and intravenous prescription drugs: switching these medication from patients’ medical benefit to their prescription drug coverage.
